In our study, the chronic inflammation was indeed present in patients with chronic renal failure, accompanied by higher IL-6 levels, which can aggravate patients’ hyporesponsive to ESAs, but inflammation does not affect the efficacy of roxadustat in the treatment of anemia which consistent with previous studies (24, 25). This evidence concerns the gene IL6 and anemia (phenotype).